L Ryvo
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
-
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Papers in
-
- Advanced Breast Cancer Therapies 6
- Oncology 5
- Cancer Treatment and Pharmacology 3
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Hiroji Iwata (4 shared papers)Sherene Loi (2 shared papers)Pauline Wimberger (2 shared papers)Hirofumi Mukai (2 shared papers)Peter Schmid (2 shared papers)Antoinette R. Tan (2 shared papers)Vassiliki Karantza (2 shared papers)Sylvia Adams (2 shared papers)
- Journals
- Cancer Research (4 papers)Annals of Oncology (2 papers)Breast Care (1 paper)Journal of Geriatric Oncology (1 paper)
- Partner nations
- IsraelJapanUnited States
In The Last Decade
L Ryvo
8 papers receiving 566 citations
L Ryvo's Hit Papers
Peers
Comparison fields: 5 of 43
- Oncology 396
- Cancer Research 111
- Immunology 153
- Pulmonary and Respiratory Medicine 122
- Molecular Biology 82
Countries citing papers authored by L Ryvo
This map shows the geographic impact of L Ryvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Ryvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Ryvo more than expected).
Fields of papers citing papers by L Ryvo
This network shows the impact of papers produced by L Ryvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Ryvo. The network helps show where L Ryvo may publish in the future.
Co-authors
The 25 scholars most cited alongside L Ryvo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 485 |
| 2 | 2013 | 41 | |
| 3 | 2018 | 23 | |
| 4 | 2016 | 15 | |
| 5 | 2012 | 4 | |
| 6 | 2016 | 2 | |
| 7 | 2017 | 1 | |
| 8 | 2013 | 1 |
About L Ryvo
L Ryvo is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Epidemiology, having authored 8 papers that have together received 572 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Cancer Treatment and Pharmacology (3 papers), Breast Cancer Treatment Studies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Estrogen and related hormone effects (1 paper), Neuroendocrine Tumor Research Advances (1 paper) and Medical Imaging Techniques and Applications (1 paper). The work is most often cited by research in Oncology (396 citations), Cancer Research (111 citations), Immunology (153 citations), Pulmonary and Respiratory Medicine (122 citations) and Molecular Biology (82 citations). L Ryvo has collaborated with scholars based in Israel, Japan and United States. Frequent co-authors include Hiroji Iwata, Sherene Loi, Pauline Wimberger, Hirofumi Mukai, Peter Schmid, Antoinette R. Tan, Vassiliki Karantza, Sylvia Adams, Rita Nanda and Kenji Tamura. Their work appears in journals such as Cancer Research, Annals of Oncology, Breast Care and Journal of Geriatric Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.